Press coverage about Galapagos (NASDAQ:GLPG) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Galapagos earned a news sentiment score of 0.24 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.4349658781428 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:
- Galapagos to enter NASDAQ Biotech Index Brussels Stock … – GlobeNewswire (press release) (globenewswire.com)
- ETFs with exposure to Galapagos NV : December 7, 2017 (finance.yahoo.com)
- Technical Views: Tracking the Numbers on Shares of Galapagos Nv (GLPG) – Lockport Press (lockportpress.com)
A number of research analysts have recently commented on GLPG shares. BTIG Research reissued a “buy” rating and set a $118.00 price objective on shares of Galapagos in a report on Monday, November 20th. Stifel Nicolaus reissued a “buy” rating and set a $120.00 price objective on shares of Galapagos in a report on Sunday, October 29th. BidaskClub raised Galapagos from a “sell” rating to a “hold” rating in a report on Thursday, August 17th. Zacks Investment Research raised Galapagos from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. Finally, Morgan Stanley reissued an “overweight” rating and set a $123.00 price objective (up previously from $92.00) on shares of Galapagos in a report on Friday, October 6th. Two analysts have rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company. Galapagos currently has an average rating of “Hold” and an average target price of $111.00.
TRADEMARK VIOLATION NOTICE: This article was first reported by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.com-unik.info/2017/12/11/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-galapagos-glpg-stock-price.html.
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.